Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-24-043893
Filing Date
2024-11-07
Accepted
2024-11-07 06:09:10
Documents
69
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 1653925
2 ex31-1.htm EX-31.1 16023
3 ex31-2.htm EX-31.2 16460
4 ex32-1.htm EX-32.1 5359
5 ex32-2.htm EX-32.2 5609
6 form10-q_chart.jpg GRAPHIC 129217
  Complete submission text file 0001493152-24-043893.txt   7316807

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE lpcn-20240930.xsd EX-101.SCH 38205
8 XBRL CALCULATION FILE lpcn-20240930_cal.xml EX-101.CAL 46218
9 XBRL DEFINITION FILE lpcn-20240930_def.xml EX-101.DEF 195514
10 XBRL LABEL FILE lpcn-20240930_lab.xml EX-101.LAB 374387
11 XBRL PRESENTATION FILE lpcn-20240930_pre.xml EX-101.PRE 315163
72 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 1222722
Mailing Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108
Business Address 675 ARAPEEN DRIVE, SUITE 202 SALT LAKE CITY X1 84108 801 994 7383
Lipocine Inc. (Filer) CIK: 0001535955 (see all company filings)

EIN.: 990370688 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36357 | Film No.: 241432911
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)